Kepler Cheuvreux downgraded Signify (SFFYF) to Reduce from Hold with a price target of EUR 18, down from EUR 25. The firm cites the company’s ...
Kepler Cheuvreux analyst Rasmus Engberg downgraded Paradox Interactive (PRXXF) to Hold from Buy with a price target of SEK 225, down from SEK ...
Co SE (KCO:GR) with a Buy rating and a price target of EUR8.10. The firm's analysts highlight the company's strategic shift towards more promising opportunities in North America and the ...
We recently compiled a list of the 10 AI News Updates Trending on Wall Street. In this article, we are going to take a look ...
Kepler Cheuvreux adjusted its stance on Signify NV (LIGHT:NV) (OTC: SFFYF), downgrading the company's stock rating from Hold to Reduce. Accompanying this downgrade, the firm also reduced Signify's ...
Kepler Cheuvreux and Centile Partners have entered a strategic partnership in a bid to establish an enhanced presence in the listed derivatives market. The collaboration will bridge Kepler Cheuvreux’s ...
Tuesday saw Kepler Cheuvreux analyst William Mackie upgrade Siemens Energy AG (ETR:ENR1n) (ENR:GR) (OTC: SMEGF) stock rating from Hold to Buy, setting a new price target at €60.50, up from the ...
Update on the Share Buyback Program and the Liquidity Agreement Period from 31 January 2025 to 5 February 2025 Share Buyback ProgramOn 22 November 2024, Bekaert announced the start of the first ...
Sales growth is expected in the low single-digit percentage range for 2025, with EBIT margin forecasted around 16%. Hansen indicated this includes contributions from recent acquisitions, which are ...
On Wednesday, Kepler Cheuvreux initiated coverage on Nexity (EPA:NEXI) SA (NXI:FP), a prominent player in the French real estate market, assigning a Hold rating to the company's shares.
Kepler Cheuvreux’s execution division KCx has expanded its execution access to the Middle East and Northern Africa (MENA). KCx’s expansion opens trading opportunities in the following countries: Dubai ...
January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage ...